Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19... see more

TSXV:VXL - Post Discussion

Vaxil Bio Ltd > https://www.precisionvaccinations.com/vaxil-bio-covid19-vacc
View:
Post by Kubota6 on Feb 15, 2021 9:57am

https://www.precisionvaccinations.com/vaxil-bio-covid19-vacc

Updated February 16, 2020
(Precision Vaccinations)

An Israel based biotech company announced that it has completed in silico analyses and believes that it has successfully identified a coronavirus vaccine candidate for the COVID-19 disease.

Vaxil Bio Ltd.’s vaccine candidate is based on unique and patent-protected signal peptide technology, utilizing Vaxil’s proprietary VaxHit™ bioinformatics platform.

Announced in a press release on February 14, 2020, this COVID-19 vaccine candidate’s design is based on successful in vivo experiments testing a tuberculosis signal peptide vaccine.

“We are very excited to have been able to isolate a preliminary (vaccine) candidate that might address the current and emerging need in such a short time,” said David Goren, Vaxil’s Chairman, and Chief Executive Officer.

Mr. Goren continued to explain in this press release that “we have identified signal peptide combinations which we believe can be effective as a prophylactic vaccine against the current coronavirus and might also demonstrate therapeutic value in the future.”
Comment by Kubota6 on Feb 15, 2021 9:58am
https://www.precisionvaccinations.com/vaxil-bio-covid19-vaccine-candidate-based-patent-protected-signal-peptide-technology
Comment by HIKER2013 on Feb 15, 2021 10:27am
Nice article  from one year ago. let's see what news comes out, Charley Farley has some great hints coming out. HR
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities